undamentalytics Newsletter
Sign in

Editas Medicine, Inc. income statement

In fiscal 2025, Editas Medicine, Inc. reported revenue of $40.5m, up 25.4% on the year before, operating income of −$160m (a -394.9% margin) and net income of −$160m, or −$1.80 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue614322191262078324147
Research and development578391971581431751781999085
General and administrative4651556568767170725046
Operating income−97−120−114−141−135−193−226−169−251−160−76
Interest expense————————024
Income tax—————00000—
Net income−97−120−110−134−116−193−220−153−237−160−74
Diluted EPS−$3.02−$2.98−$2.33−$2.68−$1.98−$2.85−$3.21−$2.02−$2.88−$1.80−$0.73
Diluted shares (average)32m40m47m50m59m68m69m76m82m89m101m
EBITDA−96−117−110−138−131−188−220−163−245−155−73

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EDIT vs SPROEDIT vs STROEDIT vs OCUL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Editas Medicine, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Editas Medicine, Inc.